1 April 2016 
EMA/CHMP/223997/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Halaven 
eribulin 
On 1 April 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Halaven. 
The marketing authorisation holder for this medicinal product is Eisai Europe Ltd. 
The CHMP adopted a new indication as follows: 
"treatment of adult patients with unresectable liposarcoma who have received prior anthracycline 
containing therapy (unless unsuitable) for advanced or metastatic disease". 
For information, the full indications for Halaven will be as follows2: 
“HALAVEN is indicated for the treatment of adult patients with locally advanced or metastatic 
breast cancer who have progressed after at least one chemotherapeutic regimen for advanced 
disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane in 
either the adjuvant or metastatic setting unless patients were not suitable for these treatments. 
HALAVEN is indicated for the treatment of adult patients with unresectable liposarcoma 
who have received prior anthracycline containing therapy (unless unsuitable) for 
advanced or metastatic disease (see section 5.1).” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
